Overgrowth syndromes are among the rarest conditions encountered within modern healthcare systems, yet their impact extends far beyond clinical diagnosis and treatment. Despite advances in genetics, precision medicine, and rare disease research, individuals living with overgrowth syndromes frequently encounter barriers related to diagnostic delays, fragmented healthcare pathways, limited public awareness, insufficient policy recognition, and inadequate social inclusion. This article argues that many challenges associated with overgrowth syndromes cannot be addressed through clinical innovation alone and instead require policy-oriented advocacy capable of influencing healthcare systems, research priorities, disability frameworks, and public institutions. Drawing upon perspectives from health policy, rare disease governance, health equity, disability studies, patient-centered care, and advocacy scholarship, the article explores how policy mechanisms can bridge the gap between clinical rarity and social recognition. Particular attention is given to diagnostic equity, multidisciplinary care, healthcare accessibility, research investment, patient participation in policymaking, and the institutional recognition of lived experience. The article proposes a policy-oriented advocacy framework that moves beyond awareness toward structural change, arguing that equitable healthcare systems must respond to need rather than prevalence. Ultimately, effective advocacy is presented as a strategy for ensuring that individuals living with rare conditions remain visible within systems that shape health, inclusion, and quality of life.